Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as ...

CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

Our approach to implementing social impact starts with our own purpose, to empower every person and every organisation on the planet to achieve more.

Shares of Sarepta Therapeutics SRPT are declining in the pre-market hours today after the announcement that it will ...

Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its ...

Sarepta Therapeutics, Inc. ( NASDAQ: SRPT) Strategic Restructure and ELEVIDYS Label Update Conference Call July 16, 2025 4:30 PM ET Douglas S. Ingram - President, CEO & Director Ian Estepan - ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a ...

Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...

People are concerned over changes to gambling deductions and new taxes passed by Congress in the Big Beautiful Bill.

Arrowhead Transit is proud to be hosting the event on Saturday, July 19th. They are grateful to Minnesota North Mesabi Range in Virginia for donating the space of their parking lot for the fun.